Clinical trials: Biopsy
Breast Cancer
A Study to Determine Biopsy Rate in Participants With a First Relapse of Breast Cancer
This is a retrospective, and observational cohort study to determine the proportion of breast cancer first relapses, that are biopsied. The duration of the study will be approximately 24 months.
- Trial name
- NCT02761616
- Testing
- eBC treated participants
- Where
- 4 sites in Argentina
- Volunteers
- 76 people
- Sponsor
- Hoffmann-La Roche
NASH
A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH
Part 1: This is a multi-center evaluation of pegozafermin (administered weekly or every other week) in a randomized, double-blind, placebo-controlled study administered for 12 weeks in participants with NASH and NAFLD at high…
- Trial name
- NCT04048135
- Testing
- Pegozafermin
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 101 people
- Sponsor
- 89bio, Inc.
Carcinoma, Non-Small-Cell Lung
A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer
The purpose of this study is to assess spontaneous residual viable tumor cells (RVT) in the surgically resected tumor (Non-small cell lung cancer [NSCLC]).
- Trial name
- NCT04951154
- Testing
- Bronchoscopic Biopsy, Blood Sample
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Janssen Research & Development, LLC
Endometriosis, Diagnosis
Proof of Concept Study to Eval MetriDx Lab-developed Test to Identify Endometriosis-specific Bio Markers
This study is testing a way to diagnose endometriosis using a uterine tissue biopsy (similar to a pap smear) as opposed to undergoing laparoscopy surgery.
- Trial name
- NCT05698212
- Testing
- MetriDx
- Where
- 3 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Hera Biotech, Inc.
Haemostasis, Healthy
Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding
This trial is conducted in the United States of the America (USA). The aim of this trial is to evaluate the effectiveness of activated recombinant human factor VII to mitigate experimentally-induced bleeding in healthy volunteers…
- Trial name
- NCT01561950
- Testing
- eptacog alfa (activated), clopidogrel
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Novo Nordisk A/S
Cancer, Lung, Cancer, Breast
Early Detection of Five Common Cancers Using the ctDNA Analysing Test
This is a multi-centre, prospective cohort study, aiming to evaluate a blood test in early detection of the four common cancers, based on the investigation of the circulating tumour DNA (ctDNA).
- Conditions
- Cancer, Lung, Cancer, Breast, Cancer Liver, Cancer, Colorectal
- Trial name
- K-DETEK (NCT05227261)
- Where
- Vietnam
- Volunteers
- 9,057 people, healthy volunteers welcome
- Sponsor
- Gene Solutions
Candidiasis, Esophageal, HIV Infections
Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients
To determine the appropriate duration of amphotericin B therapy for Candida esophagitis. To compare the effectiveness of two different amphotericin B doses in the treatment of biopsy-proven Candida esophagitis.
- Trial name
- NCT00002041
- Testing
- Amphotericin B
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Patients That Have Been Diagnosed With Colorectal Cancer, Patients Eligible for Tumor Biopsy
NovellusDx Tissue Collection Protocol
NovellusDx is developing a diagnostic platform for the personalized cancer therapy based on patient derived tumor tissue. The assay is able to sense activating mutations by monitoring their effect on a chip-based device.
- Trial name
- NCT01791322
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Fore Biotherapeutics
Prostate Cancer
Registry to Measure the Impact of Adding Genomic Testing
This is a prospective open registry to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer.
- Trial name
- NCT02454595
- Testing
- Registry
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Prostate Cancer
Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer
To Evaluate Safety, Tolerability and Potential Efficacy of PRX302 effect on clinically significant localised low to intermediate prostate cancer.
- Trial name
- NCT02499848
- Testing
- PRX302
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Sophiris Bio Corp
Breast Cancer Detection, Breast Neoplasm
Molecular Breast Imaging (MBI)-Guided Biopsy
The goal of this pilot clinical trial is to demonstrate supplemental screening MBI (molecular breast imaging) in women with dense breasts.
- Conditions
- Breast Cancer Detection, Breast Neoplasm, Molecular Imaging, Biopsy
- Trial name
- MBI-GB-Pilot (NCT07114679)
- Testing
- Molecular Breast Imaging, MBI-guided biopsy
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Smart Breast Corp.
Cancer Abdomen
Epione® Post-Market Clinical Follow-up Study
Post-Market Clinical Follow-up study in order to consolidate performance and safety data of the EPIONE® device when used for percutaneous procedures in the abdomen
- Trial name
- SaFE (NCT05529979)
- Testing
- EPIONE® CT-Guided Percutaneous procedures
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Quantum Surgical
Alpha-1 Antitrypsin Deficiency
Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels
Patients with Alpha-1 Antitrypsin Deficiency (AATD) will be enrolled to receive multiple doses of ARC-AAT Injection. All subjects will require a pre-dose biopsy and a biopsy post last dose.
- Trial name
- NCT02900183
- Testing
- ARC-AAT Injection
- Where
- 4 sites in Canada, Ireland and 2 more
- Sponsor
- Arrowhead Pharmaceuticals
Focal Segmental Glomerulosclerosis
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT07268638
- Testing
- Praliciguat (Part A), Praliciguat (Part B)
- Where
- 30 sites in United States
- Volunteers
- 60 people
- Sponsor
- Akebia Therapeutics
Right Heart Catheterization
The Nanowear Wearable System SimpleSense Validation Trial for Cardiac Output
The Nanowear SimpleSense study is a single center, prospective, non-randomized, feasibility, non- significant risk study The study will be done in 2 phases.
- Trial name
- NCT05629533
- Testing
- SimpleSense
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Nanowear Inc.
Cytopaenia
A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia
This was a non-randomized, open-label, phase II study to assess the efficacy and safety of eltrombopag in Japanese moderate or more severe aplastic anemia (AA) subjects with a platelet count <30,000/microliter who were refractory…
- Trial name
- NCT02148133
- Testing
- Eltrombopag 12.5 mg, Eltrombopag 25 mg
- Where
- 12 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial
This is a multicenter screening protocol designed to identify patients with NSCLC who have tumor mutations in the KEAP1 or NRF2/NFE2L2 genes in order to determine potential eligibility for a biomarker selected clinical trial…
- Conditions
- Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation
- Trial name
- NCT04698681
- Where
- 63 sites in United States
- Volunteers
- 20 people
- Sponsor
- Calithera Biosciences, Inc
High-risk HPV Infection and Biopsy-proven CIN1
An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101
Phase I, open-label, sequential-cohort, ascending multiple-dose study to evaluate the safety and tolerability of escalating doses of PDS0101 in female subjects with high-risk HPV infection and biopsy-proven CIN1.
- Trial name
- NCT02065973
- Testing
- R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- PDS Biotechnology Corp.
Patients With Advanced Solid Tumors
Safety and Tolerability of Intravenous Administration of ICVB-1042
Study to evaluate the safety and tolerability of intravenous ICVB-1042
- Trial name
- ICVB-1042 (NCT05904236)
- Testing
- Treatment with ICVB-1042 administered intravenously
- Where
- 10 sites in United States
- Volunteers
- 17 people
- Sponsor
- IconOVir Bio
Breast Cancer
Koning Breast Computed Tomography Guided Biopsy
The primary aim of this study is to show that the accuracy of Koning Breast CT-guided biopsy is at least equivalent to that of stereotactic-guided biopsy.
- Trial name
- NCT01750320
- Testing
- Koning Breast CT-guided Biopsy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Koning Corporation